OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Results of Phase 2 trials for Trovax and Phase 2 of MetXia due any day, these are expected to be good and with a possible announcement that ProSavin will be going into trial and new licensing agreements for it's Lentivector Technology, the next couple of mths is going to be exciting for holders of OXB, i'd expect buying in anticipation of the news and possibly 30p in January, let's see...

robstuff - are you able to say where you got the info on pending results?

Most of the info can be found on previous news more than 30days old on this site but also articles in the Shares mags, the Co has stated that progress is ahead of schedule in most fields and I'm hoping they will announce more good news this side of Xmas. Some licensing deals for it's Lentivector tech would give a much needed boost to the sp, but my feeling is that something much bigger will be announced as the Phase 11 trials near completion, and then there will be more institutional investment. Some good buys today, the 250k looks like a buy, it's also a good time of the year for OXB, as it often gets tipped at the end of yr, and for the new yr share tips, which lets face it OXB will be featured as it was last yr surely.

2005 will be the defining moment in OXB's history. Their technology and knowledge leads the field and Biotechnology will get a revived interest next yr as products near final stages of development. My quess is that OXB is due to announce something vbig and the sp will rocket. Last year it was a favourite "share of the yr play" but was a little premature, since then more good news adds to the value but the shares have fallen. We may get takeover speculation if the price hovers around these levels as one of the larger players will find OXB very attractive for the Intellectual property.

Just beginning to turn.

Trovax trial results due, I seee price rising to 30 before long, what's everybody elses view?

If the news is good, i.e. trials were successful (no news is good news) then 30p would be cheap

Buy now before 30p comes, then you'll regret

Don't you mean if you don't buy, you'll regret

One or two brokers have target of 50p next yr

Yes, but it's the house broker so treat carefully...

what are peoples thoughts on the end of year results due at trhe end of the month ???

all be careful. Does any one remember British Biotech. If trials fail then the shares will drop

That was after a massive rise in sp. This co is so rediculously cheap, and has many products in trial, then one failure will dampen theprice for a short while but then if just one gets through, the company is worth many pounds. I have a feeling that there will be good news in the trials and the sp will rise quite rapidly to 50p early next yr, and my patience will have paid off!

I agree with you rvitler. But we are investing on an "if" like most co and new investors should be careful. I do have a reasonalable holding in this company and have for a long time. I hope you feelings pay off. My patience is wearing thin. I could do with a booster in the New year.

I think we'll see it so hang on in there, starting to tick up at the moment.

Some excellent news to add to the value:

FOR IMMEDIATE RELEASE 13 DECEMBER 2004


OXFORD BIOMEDICA LICENSES RETROVIRAL EX VIVO GENE DELIVERY TECHNOLOGY
TO MOLMED SPA

Oxford, UK - 13 December 2004: Oxford BioMedica (LSE: OXB) and MolMed SpA
(Milan, Italy) today announced a licence agreement for Oxford BioMedica's
retroviral ex vivo gene delivery technology. The agreement provides MolMed with
rights to utilise this technology in the development of MolMed's product
pipeline. Under the agreement, Oxford BioMedica receives an upfront licence fee
and annual maintenance payments. In addition, Oxford BioMedica will receive
payments on the achievement of clinical and regulatory milestones by MolMed and
product royalties. Further financial details were not disclosed.

The retroviral ex vivo gene delivery technology combines Oxford BioMedica's
technology with some of the gene therapy technology acquired from Chiron
Corporation in June this year.

Oxford BioMedica's CEO, Professor Alan Kingsman, said: 'We are delighted to
welcome MolMed to the list of Oxford BioMedica's technology licensees. This
agreement provides further evidence of the breadth and strength of our
proprietary gene delivery technology.

Excellent news, and although some early sellers, the price should improve from here, quite why figures have not been disclosed is strange but that will be due to more licensing contracts currently being negotiated. The sp at some point won't look back.

A false start me thinks - see the buyers snap them up - i have!